skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8125

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Review

(1867) Views  (910) Full article downloads

Authors: Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

Published Date August 2010 Volume 2010:5 Pages 581 - 591
DOI: http://dx.doi.org/10.2147/IJN.S8603

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, Moshe Baru

Omri Laboratories Ltd., Nes Ziona, Israel

Abstract: Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injections of the missing FVIII often lead to the formation of inhibitory antibodies. Patients who develop high levels of inhibitors must be treated with bypassing agents such as activated FVII (FVIIa). Both FVIII and FVIIa have short half-lives and require multiple injections. Long-acting forms of these proteins would therefore reduce the frequency of injections, improve patient compliance and reduce complications. In this article we present a new platform technology that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia treatment. This technology is based on the binding of proteins/peptides to the outer surface of PEGylated liposomes (PEGLip). Binding is dependent on an amino acid consensus sequence within the proteins and is highly specific. At the same time, binding is non-covalent and does not require any modification of the therapeutic agent or its production process. Association of proteins with PEGLip results in substantial enhancements in their pharmacodynamic properties following administration. These improvements seem to arise from the association of formulated proteins with platelets prior to induction of coagulation.

Keywords: PEGylated liposomes, therapeutic proteins, pharmacodynamics, factor VIII, factor VIIa